November 07 , 2025

Ref:- GHL/2025-26/EXCH/77

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

Scrip Code: 543654

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Symbol: MEDANTA

Sub: Investor Presentation

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the Second Quarter and Half Year ended September 30, 2025 Results.

Kindly take the above on record.

Thanking you,

Yours faithfully

For Global Health Limited

RAHUL RANJAN Digitally signed by RAHUL RANJAN Date: 2025.11.07 17:52:25 +05'30'

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a

GLOBAL HEALTH LIMITED

Dedicated to Life

Investor Presentation

Q2 and H1 FY2026

7th November, 2025

Disclaimer

- This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.
- These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.

Contents

01

Q2 and H1 FY2026 Performance Update

Q2 FY2026 performance summary

Revenue Growth of 15% y-o-y and EBITDA growth (ex Noida) of 14% y-o-y

Total Income[1]
INR 11,189 million
Q2 FY25: 9,748 million
▲ 14.8%

EBITDA[3] ex Noida[2]
INR 2,804 million
Margin: 25.2%
Q2 FY25: 2,465 million, Margin: 25.3%
▲ 13.7%

EBITDA[3] incl. Noida
INR 2,607 million
Margin: 23.3%
Q2 FY25: 2,465 million, Margin: 25.3%
▲ 5.7%

PAT
INR 1,584 million
Margin: 14.2%
Q2 FY25: 1,308 million, Margin: 13.4%
▲ 21.1%

Occupied Bed Days
155,729
Q2 FY25: 144,564
▲ 7.7%

ARPOB* (INR)
65,570
Q2 FY25: 62,141
▲ 5.5%

ALOS (days)
3.06
Q2 FY25: 3.20
▼ -4.5%

Patient Footfalls
50,925 In-patients
▲ 12.7%
Q2 FY25: 45,169

890,750 Out-patients
▲ 14.9%
Q2 FY25: 775,395

1. Noida generated Total Income of INR 39 million in Q2 FY26
2. Noida facility resulted in EBITDA loss of INR 197 million during the quarter
3. EBITDA represents EBITDA before ESOP expenses

*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
** Outpatients volume reflects OPD encounters

Q2 FY2026 performance summary

Revenue growth of 15% y-o-y, primarily led by increase in patient volumes and realization

- Consolidated Total Income of INR 11,189 million, compared to INR 9,748 million in Q2 FY25; reflecting a growth of 14.8 % y-o-y
- EBITDA[1] (ex-Noida[3]) grew 13.7 % y-o-y to INR 2,804 with margins of 25.2% compared to 25.3% in Q2 FY25. Including Noida, EBITDA was INR 2,607 million, up 5.7% y-o-y, with margins at 23.3%
- Medanta Noida commenced operations in September 2025. The hospital generated Revenue of INR 39 million and EBITDA loss of INR 197 million
- Profit After Tax was INR 1,584 million, growth of 21.1% y-o-y. PAT margins improved to 14.2% from 13.4% in Q2 FY25
- During the quarter, 37 new beds were added at Patna, taking total bed addition to 57 beds in H1 FY26 in Patna
- Occupied bed days increased by 7.7% y-o-y, representing an occupancy of ~64% on increased bed capacity
- ARPOB grew by 5.5% y-o-y to INR 65,570 in Q2 FY26, driven by increase in realization and change in speciality mix
- Volume growth remained robust, In-patient count increased by 12.7% and Out-patient count increased by 14.9% y-o-y
- Matured hospitals revenue was INR 7,200 million, growth of 5.4% y-o-y. EBITDA was INR 1,696 million, growth of 0.4% y-o-y
- Developing hospitals ex Noida, Revenue was INR 3,531 million, growth of 28.3% y-o-y. EBITDA increased 34.0% YoY to INR 1,112 million, with margins improving to 31.5% compared to 30.1% in Q2 FY25. Including Noida, EBITDA stood at INR 915 million, up 10.2% y-o-y, with margin of 25.6%, reflecting the impact of initial ramp-up costs
- International Patients Revenue increased by 48.5% y-o-y to INR 762 million in Q2 FY26, driven by increased international patient volume
- OPD Pharmacy (Hospital & Retail) continues to register strong double digit growth. Revenue increased by 23.9% y-o-y to INR 456 million in Q2 FY26

1. EBITDA represents EBITDA before ESOP expenses
2. Noida generated Total Income of INR 39 million in Q2 FY26
3. Noida facility resulted in EBITDA loss of INR 197 million during the quarter

*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

Medanta Noida: Launched on 1st September, 2025

Commenced phase I of 300 beds; 226 beds and 5 OTs operational as at the end of Q2 FY26

Medanta Noida Overview

550+
Planned beds capacity

226
Operational beds

80+
ICU Beds

150+
Experienced Doctors

60+
Senior clinicians

500+
Nurses and paramedics

950+
Full-time employees

20+
Super Specialities



Latest advanced technology deployed at Noida

Providing the latest tools to enable our doctors to deliver the greatest care

O-arm O2 Surgical Imaging System

Da Vinci Xi Robotic System

ARTIS icono BiPlane CATH Lab

MAGNETOM Lumina 3T MRI

SOMATOM Pro. Pulse Dual Source CT

ARTIS icono Ceiling with Abbott EP System – CATH Lab

Stealth Station S8 Neuro Navigation System

Lumenis Pulse 100H Holmium Laser

ACUPULSE DUO CO2 Laser System

Leica Arveo 8 Digital Visulisation Microscope for Neurosurgery

Q2 FY2026 Business Update

Strengthening the core and building strong pipeline for growth

Capacity Expansion

- ✓ **Patna:** Total of 37 beds added in Q2 FY26. Total 57 bed addition in H1 FY26
- ✓ **Noida:** Commenced phase 1 of 300 beds in Sep 2025. Operational bed at the end of Q2 FY26 were 226 beds

New Medical Equipment Deployed in Q2 FY26 (ex Noida)

A 128 slice Dual Source CT
Medanta Lucknow

MAGNETOM Altea 1.5 Tesla MRI
Medanta Lucknow

Attract Best Talent

- ✓ **49 Doctors on-boarded in** Q2 FY26 across Medanta network hospitals excluding Noida
- ✓ **150+ doctors**; on-boarded in Noida during the quarter
- ✓ **Major on-boarding is across** key clinical departments such as Cardiac, Critical Care and Cancer

Continuity of Care

- ✓ **30+** collection centres added in Q2 FY2026, taking collections centre to ~300+
- ✓ **17 operational pharmacy** comprising of, 7 Pharmacies in the Hospital, 2 Mediclinics and 8 Retail Pharmacies

Key operating metrics: Revenue and profitability

Revenue growth of 14% y-o-y and 6% on a sequential basis and EBITDA up by 14% (ex Noida)

Total Income (INR million)



EBITDA[1] (INR million and margin %)



Profit before tax (INR million and margin%)



Profit after tax (INR million and margin %)



1. EBITDA represents EBITDA before ESOP expenses
***Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include Lucknow Unit. Accordingly all comparative period also include Lucknow unit numbers*

Key operating metrics: Volumes, occupancies, ALOS

Occupied bed days grew by 8%, driven by in-patient volume growth of 13% y-o-y, occupancy at 64% in Q2 FY26

Average census and occupied beds



ALOS (days)



IPD volumes ('000)



OPD volumes ('000)



Key operating metrics: ARPOB and revenue mix

ARPOB growth driven change in specialty mix; cancer contribution is increasing

ARPOB* (INR)



IPD Revenue mix by payor category



Domestic and international revenue breakdown



IPD vs OPD revenue breakdown



*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

Diverse revenue[1] mix

Significant contribution from complex specialties. Cancer contribution is increasing



Notes:
1. Revenue from healthcare services excludes pharmacy revenue and other income
2. Revenue breakdowns are provided as per internal MIS at the Company's consolidated level
3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery

*Previous period figures have been regrouped/reclassified to conform to the current period's classification. Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include MHPL

Growth seen in both mature and new hospitals

Developing hospitals delivered robust revenue and EBITDA y-o-y growth

Matured hospitals - Over 6 years

Total Income (INR million)



EBITDA (INR million and margin %)



IPD Volumes (count)



ARPOB* (INR)



Developing hospitals - Less than 6 years

Total Income (INR million)



EBITDA (INR million and margin %)



IPD Volumes (count)



ARPOB* (INR)



*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

- *Previous period figures have been regrouped/reclassified to conform to the current period's classification*

H1 FY2026 performance summary

Well capitalized balance sheet and strong EBITDA to cash flow conversion

INR million	FY2022	FY2023	FY2024	FY2025	H1 FY2026
Gross Debt	8,379	8,422	4,193	3,279	**5,267**
Cash and Cash Equivalents	5,222	13,114	11,913	11,402	**12,349**
Net Debt / (Net Cash)	**3,156**	**(4,692)**	**(7,720)**	**(8,123)**	**(7,082)**
Shareholder Equity	16,160	24,282	29,056	33,864	**37,075**
Net Debt to Equity (x)	**0.2x**	**-**	**-**	-	**-**
Net Cash flow from Operations	3,113	6,445	6,121	6,238	**3,295**
EBITDA[1]	4,898	6,771	8,737	9,562	**5,161**
Cash Flow Conversion (%)	**64%**	**95%**	**70%**	**65%**	**66%**
Net Debt to EBITDA (x)	**0.6x**	**-**	**-**	**-**	**-**

Key Highlights

- Gross Debt increased by INR 1,988 million primarily due to loan drawdown for Noida project
- Net Cash surplus of INR 7,082 million at the end of 30th September, 2025
- Strong operating cash flow with robust EBITDA to cash flow conversion
- Capex of INR 4,252 million incurred during the period
- Well capitalized balance sheet to drive future expansion plans and growth

1. EBITDA represents EBITDA before ESOP expenses

02 Project Update and Capex Plan

Guwahati project update: Bhoomi Poojan ceremony held on 31st October, 2025

- ✓ **Land Parcel Offered**: Acquired 3.5-acre land parcel with a cost of ~Rs. 600 million
- ✓ **Strategic Location:** Newly offered land is situated along the National Highway 27
- ✓ **Enhanced Accessibility**: Prime location ensures easier access for patients and families covering entire north east region
- ✓ **Critical Advantage:** Ideal for emergency and critical care access due to improved connectivity
- ✓ Allotment, possession and lease deed executed

Allotment Letter Received on 24th October, 2025

Possession Taken on 27th October, 2025

Bhumi Poojan on 31st October, 2025

Medanta Mumbai to now became a ~750 bed hospital

Super specialty hospital in Oshiwara, Mumbai

*The artistic image for illustration purpose only

- ✓ The Company has bought 8,859 sq. meters of land in Oshiwara from MHADA for an amount of Rs. 125.11 crores in a public auction
- ✓ Final plot area is now 9,287.54 sqm after final measurement and company has paid Rs. 6.05 crores for additional area of 428.34 sqm
- ✓ Barricading of the site has been completed. IOA approval has been obtained, application for commencement of construction upto plinth level filed
- ✓ Soil testing is complete, and the structural consultant is currently designing the shoring, excavation, and basement construction plan based on the test results
- ✓ **Additional FSI approval received and the increased FSI has raised the allowable built-up area to 1,25,382 sq. m., enabling an increase in bed capacity from 500 to 750**
- ✓ **The facility is now expected to have a capacity of 750 beds** and will set new benchmarks in healthcare delivery, providing world-class medical services and advanced treatment options to the residents of Mumbai and surrounding regions
- ✓ **The project cost is estimated to be ~INR. 15,300 million.** The project cost includes Land cost, additional FSI purchase as well as an investment of up to INR 850 million for residential apartments for Medanta staff

On-going expansion projects

Planned bed capacity addition; well positioned to drive near term growth

Number of installed beds



- **Patna:** Total 37 beds added in Q2 FY2026 and 20 beds added in Q1 FY2026
- **Ranchi:** Newly built 110 bedded hospital in Ranchi, operationalized in July 2025
- **Noida with total capacity of 550 beds:** Noida commenced phase 1 of 300 beds in September, 2025 with 226 operational beds at the end of Q2 FY2026
- **South Delhi:** Announced 400 bed in partnership with DLF. Site survey complete, soil testing complete. Barricading and construction is in progress
- **Pitampura, New Delhi:** Signed O&M Agreement to jointly build and operate and manage a ~750 bed hospital. Architectural drawings submitted
- **Mumbai:** Land acquired in Mumbai in October 2024. Additional FSI approval received. Building plan currently under preparation
- **Guwahati, Assam:** Land acquisition and possession have been completed. Bhoomi Poojan ceremony held on 31st October 2025

Indore: : A 300-bed facility was announced in partnership with a real estate partner. However, the project is currently under review by the company due to ongoing legal proceedings involving the erstwhile owner. Given the uncertainty around timelines, the project has been excluded from the current bed build-out plan.*

Capex plan next 5 years

Total capex of over ~INR 41,200 million planned for next 5 years



- In H1 FY2026, **INR 4,252 million of capex incurred**
- **Maintenance capex estimated at INR ~4,500 million** to be incurred over next three years
- **Total Project capex estimated at INR ~36,700 million,** to be funded by combination of Debt funding and internal accruals

03

Medanta's Journey, Purpose and Model of Healthcare

Medanta was founded to bring a new type of healthcare to India…

… the human side of healthcare

Healthcare is never only about science. It is also about the art of medicine – the human connection, putting the patient first, collaboration, the personal acts of empathy and the values that guide our decision making.

“At Medanta we have built an institution to match the highest benchmarks of excellence globally. We have created an ecosystem of excellence that encompasses world-leading clinicians, state-of-the-art equipment, best-in-class infrastructure, and a strong emphasis on research and innovation.

Medanta’s patient-first approach allows teams of super-specialist doctors to collaborate seamlessly and arrive at the best-possible treatment customized for each patient in line with our guiding philosophy ‘Har Ek Jaan Anmol’, meaning ‘Every Life is Invaluable’”

Dr. Naresh Trehan
CMD & Chief Cardiac Surgeon, Medanta

Growth from a single flagship hospital in Gurgaon…

…to a network of 6 high quality hospitals across north India

2009
MEDANTA
THE MEDICITY
Gurgaon
1,440 Beds
316 ICU Beds

CARLYLE

2013
Carlyle* buys minority stake in December

2014
MEDANTA
SUPER SPECIALTY
HOSPITAL
INDORE
175 Beds
53 ICU Beds

2015
MEDANTA ABDUR RAZZAQUE ANSARI MEMORIAL WEAVERS HOSPITAL
RANCHI
200 Beds
54 ICU Beds

TEMASEK

2015
Temasek buys minority stake in January

2019
MEDANTA
HOSPITAL
LUCKNOW
950 Beds
757 currently operational including 202 ICU beds

2021
JAI PRABHA MEDANTA SPECIALTY HOSPITAL
PATNA
650 Beds
527 currently operational including 147 ICU beds

IPO

2022
Global Health Ltd IPO listed on BSE and NSE on 16th November*

2025
MEDANTA
HOSPITAL
Ranchi**
110 Beds
Commence operations in July 2025

FY2026
MEDANTA
HOSPITAL
NOIDA
550 Beds
Commence operations in September 2025 with 226 beds including 81 ICU beds

- *Carlyle Group (Anant Investments) exited completely in the IPO
- ** Medanta to operationalize ~110 bedded newly built hospital in Ranchi under an O&M arrangement

From our flagship Medicity campus in Gurgaon, we have grown to ~3,435 beds across 6 cities

Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar

Gurgaon
1,440 beds; 316 ICU beds

LUCKNOW
757 beds; 202 ICU beds (950 planned)

PATNA
527 beds; 147 ICU beds (650 planned)

INDORE
175 beds; 53 ICU beds

RANCHI*
310 beds; 102 ICU beds

NOIDA
226 beds; 81 ICU beds (550 planned)

All beds are installed beds as at September 30, 2025
* Medanta has signed an O&M agreement to manage for a ~110 bedded newly built hospital in Ranchi

One of the largest private hospital chains in North and East India

Serving over 400 million people in the States with Medanta facilities

Delhi; ~1,150 bed addition planned with 750 beds in Pitampura and 400 beds in South Delhi

Gurugram; Largest single location private hospital in with operational bed capacity of **1,440**

Noida; 550 beds super speciality hospital commence operations in sept 2025

Guwahati; Planned 400 bed super-specialty hospital to serve entire Northeast region

Lucknow; Largest private hospital in Uttar Pradesh with planned bed capacity of **950**

Indore; 175 bedded hospital

Patna; Largest private hospital in Patna with planned bed capacity of **650**

Mumbai; ~750 beds super speciality hospital under construction at Oshiwara

Ranchi; 2nd largest private hospital in Ranchi bed capacity of **200**
New 110 bedded hospital operations in July 2025 under an O&M arrangement



Existing Hospital | Upcoming Hospital

Medanta Labs | Medanta Clinics

Our Network

Hospital Network		Bed Capacity		Infrastructure	
6	Multi-speciality hospitals	3,435	Total Beds	900+	ICU Beds
4	Upcoming hospitals	~2,900+	Planned Bed Addition	85+	Operating Theatres

Continuity of care

Medanta Clinics	Medanta Labs	Pharmacy
8 Clinics	12 Labs total	17 Pharmacy
5 cities	300+ Collection centre	4 Planned

Our People

Doctors	Nurses and paramedics	Full-time and retainer employees
2,150+	7,800+	13,250+

Our Mission and Values

Embracing a new era and redefining our purpose

MISSION

Our mission is to deliver world class, patient centric, integrated and affordable healthcare through a dynamic institution that focuses on the development of people and knowledge

Core Values

Patient centric care: Foster a culture where every one of us is committed to care for patients and their caregivers

Leadership and quality: Commit to delivering excellence in everything we do through exemplary action and behaviour

Integrity and courage: Maintain the highest ethical standards by putting the patient first and demonstrating the courage to do what is right

Collaboration, learning and innovation: Promote teamwork and collaboration, welcome change and creativity, encourage innovation

The Medanta Model of Healthcare

Delivering the highest quality of medicine with care and compassion

Exceptional clinical talent

Trust based compassionate care



World class Infrastructure

Caring systems and processes

Latest high end technology

What it means for patients and caregivers?

- Super specialized doctors provide the highest quality of care through a team based integrated approach
- A safe and friendly healing environment with a patient-centric design in all clinical areas and public spaces
- Availability of the most advanced, innovative equipment and technology to enable the most complex diagnostics and treatment
- Doctors who take ownership and personal responsibility
- Respect-based processes for patients and their families

Medanta is well placed to deliver sustainable growth…

…while maintaining its core values of patient centric care and clinical leadership and quality

BED EXPANSION
In existing and new hospitals

ATTRACT BEST TALENT
Engage prominent, skilled clinical talent

ENHANCE CAPABILITIES
Add new specialties and improve operating efficiencies

TECHNOLOGY ADVANCEMENT
Use technology to improve patient experience and grow digital health

CONTINUITY OF CARE
Extend clinical services outside hospital and across patient lifetime

THOUGHT LEADERSHIP
Build on our thought leadership through academics and research

04 Annexures

Annexure: Profit and Loss Statement

INR million	Half Year H1 FY25	H1 FY26	Y-o-Y Growth %	Quarter Q2 FY25	Q1 FY26	Q2 FY26	Y-o-Y Growth %
Revenue from operations	**18,176**	**21,301**	***17.2%***	**9,566**	**10,308**	**10,992**	***14.9%***
Other income	401	402	*0.1%*	182	205	197	*8.3%*
Total income	**18,578**	**21,702**	***16.8%***	**9,748**	**10,513**	**11,189**	***14.8%***
Cost of materials consumed	4,368	4,946	*13.2%*	2,280	2,391	2,556	*12.1%*
Employee benefits expense	6,563	8,045	*22.6%*	3,366	3,852	4,193	*24.6%*
Other expenses	3,099	3,551	*14.6%*	1,637	1,717	1,834	*12.1%*
EBITDA	**4,548**	**5,160**	***13.5%***	**2,465**	**2,553**	**2,607**	***5.7%***
EBITDA Margins %	***24.5%***	***23.8%***	***(70) bps***	***25.3%***	***24.3%***	***23.3%***	***(199) bps***
ESOP Expenses	0	179	*na*	0	79	100	*na*
EBITDA after ESOP Expenses	**4,548**	**4,981**	***9.5%***	**2,465**	**2,474**	**2,507**	***1.7%***
Finance costs	340	309	*(9.0)%*	160	138	171	*7.1%*
Depreciation and amortisation expense	960	948	*(1.3)%*	494	451	497	*0.6%*
Exceptional item	0	(356)	*na*	0	(196)	(160)	*na*
Profit before tax	**3,248**	**4,080**	***25.6%***	**1,811**	**2,081**	**1,998**	***10.3%***
Tax expenses	877	906	*3.3%*	503	492	414	*(17.7)%*
Profit after tax	**2,371**	**3,174**	***33.9%***	**1,308**	**1,590**	**1,584**	***21.1%***

*In Q2 FY26, Company reversed stamp duty payable on account of the merger of MHPL with GHL, amounting to Rs. 159.85 millions, pursuant to adjudication of its stamp duty application
**In Q1 FY26, PAT is higher due to non-recurring exceptional income of Rs. 196 million arising due to reversal of potential interest liability on EPCG following transfer of EPCG licenses from MHPL to GHL.
****Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include Lucknow Unit. Accordingly all comparative period also include Lucknow unit numbers*

Annexure: Operational Parameters

Key metrics	Year End H1 FY25	H1 FY26	Y-o-Y Growth %	Quarter Q2 FY25	Q1 FY26	Q2 FY26	Y-o-Y Growth %	Q-o-Q Growth %
Total Beds	3,008	**3,435**	*14.2%*	3,008	3,062	**3,435**	*14.2%*	*12.2%*
Census Beds	2,400	**2,573**	*7.2%*	2,446	2,487	**2,658**	*8.7%*	*6.9%*
Occupied Bed Days	2,70,636	**2,98,627**	*10.3%*	1,44,564	1,42,898	**1,55,729**	*7.7%*	*9.0%*
Occupancy Rate %	*61.6%*	**63.4%**	*2.9%*	*64.3%*	*63.2%*	**63.7%**	*(60),bps*	*1.4%*
ARPOB (INR)*	63,024	**66,055**	*4.8%*	62,141	66,584	**65,570**	*5.5%*	*(1.5)%*
ALOS (days)	3.13	**3.04**	*(2.7)%*	3.20	3.03	**3.06**	*(4.5)%*	*0.9%*
In-Patient Volumes	86,462	**98,075**	*13.4%*	45,169	47,150	**50,925**	*12.7%*	*8.0%*
Out-Patient Volumes	14,99,087	**17,09,565**	*14.0%*	7,75,395	8,18,815	**8,90,750**	*14.9%*	*8.8%*

- Census Beds as based on monthly average during the period
- ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
- Out-Patient volumes are sum of encounters at Out-Patient departments

Annexure: Abbreviations and Definitions

Abbreviations

- INR : Indian Rupee
- NABH : National Accreditation Board for Hospitals & Healthcare Providers
- NABL : National Accreditation Board for Testing and Calibration Laboratories
- JCI : Joint Commission International
- OPD : Out-Patient Department
- IPD : In Patient Department
- ICU : Intensive Care Unit
- Mn : Million
- ARPOB : Average Revenue Per Occupied Bed
- ALOS : Average Length of Stay
- EBITDA: EBITDA represents Profit before tax after adding back finance costs, ESOP expenses and depreciation and amortization of the relevant year/period
- EBITDA Margin : EBITDA divided by Total Income in percentage
- PAT : Profit After Tax
- NCR : National Capital Region

Definitions

- Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other bed available other than census beds, i.e., day-care beds).
- Occupied beds : Total Count of patients at midnight at each day
- Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catherization & Observation room
- ICU Beds: No of ICU Beds available in the hospital out of census beds
- Total Income : Revenue from Operations + Other Income
- ARPOB : Income from Health Care Services excluding Pharmacy and Other Income revenue divided by occupied bed days
- ALOS : Average number of days spent by admitted inpatients
- Revenue mix by Payment Type, i.e. Cash, TPA,CGHS, ECHS, PSU others.

Contact us

About Medanta

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the "Company") is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled "An assessment of the healthcare delivery market in India, September 2022" by CRISIL Limited.

Under the "Medanta" brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,435 installed beds as on Sep 30, 2025. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 2,000+ doctors led by highly experienced department heads.

Contact Details

Ravi Gothwal –

Head of Investor Relations

+91 95996 55711

ravi.gothwal@medanta.org

Corporate Office

Medanta; The Medicity

CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurgaon, Haryana 122001

For further information, please visit our website:

https://www.medanta.org/